Market closed
Design Therapeutics/$DSGN
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Design Therapeutics
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
Ticker
$DSGN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
54
Website
DSGN Metrics
BasicAdvanced
$280M
-
-$0.85
1.83
-
Price and volume
Market cap
$280M
Beta
1.83
52-week high
$6.95
52-week low
$2.25
Average daily volume
207K
Financial strength
Current ratio
34.613
Quick ratio
34.345
Long term debt to equity
0.691
Total debt to equity
0.999
Management effectiveness
Return on assets (TTM)
-13.54%
Return on equity (TTM)
-17.78%
Valuation
Price to book
1.11
Price to tangible book (TTM)
1.11
Price to free cash flow (TTM)
-6.008
Growth
Earnings per share change (TTM)
-34.57%
3-year earnings per share growth (CAGR)
-5.03%
What the Analysts think about DSGN
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Design Therapeutics stock.
DSGN Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
DSGN Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
DSGN News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Design Therapeutics stock?
Design Therapeutics (DSGN) has a market cap of $280M as of January 31, 2025.
What is the P/E ratio for Design Therapeutics stock?
The price to earnings (P/E) ratio for Design Therapeutics (DSGN) stock is 0 as of January 31, 2025.
Does Design Therapeutics stock pay dividends?
No, Design Therapeutics (DSGN) stock does not pay dividends to its shareholders as of January 31, 2025.
When is the next Design Therapeutics dividend payment date?
Design Therapeutics (DSGN) stock does not pay dividends to its shareholders.
What is the beta indicator for Design Therapeutics?
Design Therapeutics (DSGN) has a beta rating of 1.83. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.